A new genomic test (Decipher) from GenomeDx identifies men who after radical surgery for prostate cancer have a higher risk of the disease progression and may benefit from adjuvant radiation treatment
GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier February 10 GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined…